Admedus Limited (ASX:AHZ) today announced that its Transcatheter Aortic Valve Replacement (TAVR) device project passed a key developmental milestone by achieving the durability benchmark of 200 million cycle tests as required by the standard (ISO 5840-2:2015) for cardiovascular implants – “Cardiac valve prostheses Part 2: Surgically implanted heart valve substitutes”. This follows the announcement in October 2017, that Admedus submitted two separate IP applications in the United States for the development and manufacture of a three-dimensional replacement heart valve using Admedus’ clinically superior proprietary ADAPT technology that requires minimal suturing; and a hydro-packaging system to revolutionise the way TAVR products are assembled and distributed. Since lodging the IP applications, Admedus has actively continued the research and development phase of the project which potentially offers a long-term opportunity to enter the global TAVR market that is currently worth an estimated $US3B and projected to reach $US5B by 2020.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.